tradingkey.logo
搜尋

60 Degrees Pharmaceuticals Inc

SXTP
添加自選
1.710USD
-0.040-2.29%
收盤 07/02, 13:00美東報價延遲15分鐘
1.75M總市值
虧損本益比TTM

60 Degrees Pharmaceuticals Inc

1.710
-0.040-2.29%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.29%

5天

+6.21%

1月

+11.76%

6月

-17.14%

今年開始到現在

-15.90%

1年

-28.15%

關鍵數據
1.670今開
1.820最高
24.77K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
2.41%換手率
1.750昨收
1.670最低
36.22K成交額
虧損本益比靜
-0.34市淨率
0.00%股息率 TTM
-119.00%ROA
14.68052週最高
0.49量比
-8.43M淨利潤
1.03M總股本
-6.8035每股盈餘TTM
--Beta
--ROE
1.29052週最低
8.57%振幅
47.12%毛利率
1.75M總市值
1.97回報/風險
7.30%風險率

操作建議

60 Degrees Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在藥品行業排名121/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為3.70。中期看,股價處於平穩狀態。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

60 Degrees Pharmaceuticals Inc評分

相關信息

行業排名
121 / 157
全市場排名
405 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

60 Degrees Pharmaceuticals Inc亮點

亮點風險
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
業績高增長
公司營業收入穩步增長,連續3年增長455.70%
業績增長期
公司處於發展階段,最新年度總收入1.41M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入1.41M美元
估值合理
公司最新PE估值-0.25,處於3年歷史合理位
機構加倉
最新機構持股228.38K股,環比增加38.27%

分析師目標

基於 2 分析師
買入
評級
3.700
目標均價
+111.43%
漲幅空間

60 Degrees Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

60 Degrees Pharmaceuticals Inc簡介

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
公司代碼SXTP
公司60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
網址https://60degreespharma.com/

常見問題

60 Degrees Pharmaceuticals Inc(SXTP)的當前股價是多少?

60 Degrees Pharmaceuticals Inc(SXTP)的當前股價是 1.71。

60 Degrees Pharmaceuticals Inc 的股票代碼是什麼?

60 Degrees Pharmaceuticals Inc的股票代碼是SXTP。

60 Degrees Pharmaceuticals Inc股票的52週最高點是多少?

60 Degrees Pharmaceuticals Inc股票的52週最高點是14.68。

60 Degrees Pharmaceuticals Inc股票的52週最低點是多少?

60 Degrees Pharmaceuticals Inc股票的52週最低點是1.29。

60 Degrees Pharmaceuticals Inc的市值是多少?

60 Degrees Pharmaceuticals Inc的市值是1.75M。

現在60 Degrees Pharmaceuticals Inc(SXTP)的股票是買入、持有還是賣出?

根據分析師評級,60 Degrees Pharmaceuticals Inc(SXTP)的總體評級為買入,目標價格為3.70。

60 Degrees Pharmaceuticals Inc(SXTP)股票的每股收益(EPS TTM)是多少

60 Degrees Pharmaceuticals Inc(SXTP)股票的每股收益(EPS TTM)是-11.74。